114 related articles for article (PubMed ID: 25630658)
21. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI.
Zhu M; Chen Q; Liu X; Sun Q; Zhao X; Deng R; Wang Y; Huang J; Xu M; Yan J; Yu J
FEBS J; 2014 Aug; 281(16):3766-75. PubMed ID: 24988946
[TBL] [Abstract][Full Text] [Related]
22. The oncogene ERG: a key factor in prostate cancer.
Adamo P; Ladomery MR
Oncogene; 2016 Jan; 35(4):403-14. PubMed ID: 25915839
[TBL] [Abstract][Full Text] [Related]
23. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
Börno ST; Fischer A; Kerick M; Fälth M; Laible M; Brase JC; Kuner R; Dahl A; Grimm C; Sayanjali B; Isau M; Röhr C; Wunderlich A; Timmermann B; Claus R; Plass C; Graefen M; Simon R; Demichelis F; Rubin MA; Sauter G; Schlomm T; Sültmann H; Lehrach H; Schweiger MR
Cancer Discov; 2012 Nov; 2(11):1024-35. PubMed ID: 22930729
[TBL] [Abstract][Full Text] [Related]
25. A decrease in miR-150 regulates the malignancy of pancreatic cancer by targeting c-Myb and MUC4.
Yang K; He M; Cai Z; Ni C; Deng J; Ta N; Xu J; Zheng J
Pancreas; 2015 Apr; 44(3):370-9. PubMed ID: 25522282
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
27. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Wu Z; He B; He J; Mao X
Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
[TBL] [Abstract][Full Text] [Related]
29. Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer.
Acharya S; Anand S; Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
J Biol Chem; 2023 Jan; 299(1):102725. PubMed ID: 36410437
[TBL] [Abstract][Full Text] [Related]
30. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
31. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic effect of miR-125b is enhanced by the prostaglandin endoperoxide synthase 2/cyclooxygenase 2 blockade and hampers ETS1 in the context of the microenvironment of bone metastasis.
Maroni P; Bendinelli P; Matteucci E; Desiderio MA
Cell Death Dis; 2018 May; 9(5):472. PubMed ID: 29700305
[TBL] [Abstract][Full Text] [Related]
34. ERG upregulation and related ETS transcription factors in prostate cancer.
Rostad K; Mannelqvist M; Halvorsen OJ; Oyan AM; Bø TH; Stordrange L; Olsen S; Haukaas SA; Lin B; Hood L; Jonassen I; Akslen LA; Kalland KH
Int J Oncol; 2007 Jan; 30(1):19-32. PubMed ID: 17143509
[TBL] [Abstract][Full Text] [Related]
35. miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.
Seashols-Williams SJ; Budd W; Clark GC; Wu Q; Daniel R; Dragoescu E; Zehner ZE
PLoS One; 2016; 11(7):e0159601. PubMed ID: 27447934
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of ETS family members in prostate cancer tissues and androgen-sensitive and insensitive prostate cancer cell lines.
Adler D; Lindstrot A; Langer B; Buettner R; Wernert N
Int J Mol Med; 2011 Jul; 28(1):89-93. PubMed ID: 21491078
[TBL] [Abstract][Full Text] [Related]
37. c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development.
Lin YC; Kuo MW; Yu J; Kuo HH; Lin RJ; Lo WL; Yu AL
Mol Biol Evol; 2008 Oct; 25(10):2189-98. PubMed ID: 18667440
[TBL] [Abstract][Full Text] [Related]
38. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
39. Luteolin Inhibits Ischemia/Reperfusion-Induced Myocardial Injury in Rats via Downregulation of microRNA-208b-3p.
Bian C; Xu T; Zhu H; Pan D; Liu Y; Luo Y; Wu P; Li D
PLoS One; 2015; 10(12):e0144877. PubMed ID: 26658785
[TBL] [Abstract][Full Text] [Related]
40. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.
D'Aguanno S; Valentini E; Tupone MG; Desideri M; Di Martile M; Spagnuolo M; Buglioni S; Ercolani C; Falcone I; De Dominici M; Milella M; Rizzo MG; Calabretta B; Cota C; Anichini A; Trisciuoglio D; Del Bufalo D
J Exp Clin Cancer Res; 2018 Nov; 37(1):278. PubMed ID: 30454024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
